A leading COVID-19 vaccine manufacturer that uses TriLink’s CleanCap® reagent in their formulation processes needed to rapidly scale-up production and analytical testing capabilities to meet aggressive timelines and help to halt the global pandemic.
TriLink successfully increased CleanCap reagent production by 9x in 6 months via a massive expansion of our ISO-certified manufacturing space. This enabled us to provide substantial amounts of the highest-quality product to vaccine manufacturing facilities in the U.S., Asia, and Europe—accelerating the vaccine’s development for improved health outcomes across the globe.
With the dramatic growth of our ISO-certified manufacturing space, we are poised to address your most difficult scalability challenges early in development. Our flexible solutions ensure optimal scalability and faster production. We have the experience and means to help you succeed at every step of the way.
For more information on how we met and exceeded supply needs for a leading COVID-19 vaccine, download the full case study.
